ASP546C for Gastric Cancer

This trial aims to determine the optimal dose of a new treatment, ASP546C, for individuals with certain cancers, including gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other solid tumors. The study consists of two parts. In Part 1, participants with gastric or GEJ cancer will receive either a higher or lower dose of ASP546C. In Part 2, participants with pancreatic or other specific tumors will receive a higher dose. This trial may suit those diagnosed with these cancers who have already undergone at least one treatment. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor to get specific guidance based on your situation.

Research has shown that ASP546C is being tested for safety and effectiveness in treating stomach cancer and other solid tumors. Although limited information is available, the trial phase indicates that ASP546C has already undergone human testing, suggesting some level of safety.

ASP546C is administered as an infusion, slowly injected into a vein every three weeks. Similar treatments in past studies have generally been well-tolerated. However, specific side effects for ASP546C have not been detailed in the available information.

Researchers are excited about ASP546C because it offers a new approach to treating advanced gastric and other types of cancer. Unlike traditional chemotherapy, which kills rapidly dividing cells indiscriminately, ASP546C specifically targets cancer cells, potentially reducing damage to healthy cells and minimizing side effects. This precision targeting could lead to better outcomes for patients with cancers that are difficult to treat, like pancreatic adenocarcinoma and various pan-tumor types, including cholangiocarcinoma and colorectal adenocarcinoma. Additionally, ASP546C is administered intravenously every three weeks, which might improve convenience for patients compared to more frequent dosing schedules of some existing treatments.

Research has shown that ASP546C targets a protein called CLDN18.2, often present in certain cancers like stomach and pancreatic cancers. Early results suggest this method might work because the drug can attach to cancer cells and help destroy them. In this trial, participants with stomach cancer will receive either a lower or higher dose of ASP546C. Promising results from previous studies showed some tumors shrank. For pancreatic cancer, participants will receive a higher dose, and early data suggests better survival rates compared to past treatments. Although it's still early, these findings offer hope that ASP546C could be a promising treatment option for these difficult-to-treat cancers.¹²⁴⁶⁷